[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"orthostatic-hypotension-dysautonomic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:orthostatic-hypotension-dysautonomic":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,59,86,117],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100580737","cardiovascular-function-and-response-to-stimulation-within-the-first-year-after-spinal-cord-injury-100580737",false,"NCT06841198","Cardiovascular Function and Response to Stimulation Within the First Year After Spinal Cord Injury","Assessing Cardiovascular Effects: Is There a Time Too Early for Spinal Stimulation in Acute SCI? A Year-Long Evaluation of Autonomic Function Following Injury","For the main study:\n\nInclusion Criteria:\n\n* Individuals with a spinal cord injury undergoing inpatient rehabilitation at the Kessler Institute for Rehabilitation\n* Between 18-75 years old\n* 7-50 days after injury\n* Injury level ≥ T6 (a cervical or a high-level chest injury)\n* Individuals experiencing low blood pressure after the injury\n* American Spinal Injury Association Impairment Scale (AIS) A or B\n\nExclusion Criteria:\n\n* A ventilator is needed for breathing.\n* Devices such as brain\u002Fspine\u002Fnerve stimulators, a cardiac pacemaker\u002Fdefibrillator, or intra-cardiac lines are present in the body.\n* There is a significant disease affecting the blood vessels or signals in the heart, or a recent heart attack (myocardial infarction) has occurred.\n* A new medication has been prescribed to treat blood pressure or a heart problem within the last five days (excluding midodrine).\n* There is a known infection in the body (e.g., urinary tract infection) or a current illness (e.g., recent diagnosis of deep vein thrombosis (DVT) or other blood clotting issues, and\u002For a pressure injury that might interfere with the study).\n* There is a history of seizures.\n* Pregnancy.\n\nFor the spin-off study ice-water vs ice-wrap test (see description in study arms):\n\n\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n\nInclusion:\n\nAge 18-75.\n\nInclusion for individuals with SCI:\n\n* Injury sustained more than 6 months ago\n* Injury level ≥ T6 (a cervical or a high-level chest injury)\n* American spinal injury association impairment scale (AIS) A - D\n\nExclusion:\n\nFoot lesions, uses a ventilator, devices such as brain\u002Fspine\u002Fnerve stimulators, significant or recent cardiovascular disease, known infection in the body",true,"ALL","18 Years","75 Years",{"count":21,"type":22},15,"ESTIMATED","INTERVENTIONAL",[25],"NA","The study aims to explore how cardiovascular function changes in the first year after a spinal cord injury, and to see how different treatments, like spinal stimulation through the skin (transcutaneous spinal stimulation), affect blood pressure.\n\nThe main questions are:\n\nHow does stimulation affect blood pressure over the year? What is the level of cardiovascular activation throughout the year?\n\nThe study will start during the inpatient stay at the Kessler Institute for Rehabilitation and continue after discharge as an outpatient, totaling about 20-29 sessions over the year.",[28,29,30,31],"Spinal Cord Injuries (SCI)","Orthostatic Hypotension, Dysautonomic","Cardiovascular","Transcutaneous Spinal Stimulation",[33,34,35,36,37,38,39,40,41,42,43,44,45],"Transcutaneous Spinal Cord Stimulation","spinal cord stimulation","orthostatic hypotension","blood pressure","cardiovascular","neuromodulation","acute spinal cord injury","chronic spinal cord injury","inpatient rehabilitation","tilt testing","cold pressor test","ambulatory blood pressure monitoring","autonomic dysfunction following spinal cord injury","RECRUITING","2026-06-26",{"date":49,"type":50},"2026-07-01","ACTUAL",{"date":52,"type":50},"2025-04-01",{"date":54,"type":22},"2026-11",{"name":56,"class":57},"Kessler Foundation","OTHER",1,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":23,"phases":69,"briefSummary":72,"conditions":73,"keywords":76,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":83,"locationsCount":85},"100579992","phase-1-feasibility-study-assessing-the-effect-of-carbidopalevodopa-ratio-on-orthostatic-hypotension-in-multiple-system-atrophy---parkinsonian-type-and-parkinson-disease-100579992","NCT06831500","Feasibility Study Assessing the Effect of Carbidopa\u002FLevodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease.","A Monocentric, Randomized, Double-blind Study to Assess the Feasibility of Conducting a Full-scale Randomized Controlled Trial (RCT) Assessing the Effect of Carbidopa\u002FLevodopa Ratio on Orthostatic Hypotension (OH) in Multiple System Atrophy - Parkinsonian Type (MSA-P) and Parkinson Disease (PD) Patients (CARBIDOH)","CARBIDOH","Inclusion Criteria:\n\n1. Informed consent form signed.\n2. Patient over 18 years and under 80 years of age.\n3. Patient with Multiple System Atrophy- Parkinsonian type (MSA-P) (confirmed by diagnostic criteria for clinically established and clinically probable multiple system atrophy (11); OR Patient with Parkinson Disease (PD) (12) presenting OH symptoms (getting at least one point at the 3 questions - n° 14, 15 and 16 - of the SCOPA-AUT scale that address orthostatic hypotension symptoms).\n4. Patient currently receiving Dopamine-Replacement Therapy (i.e. Levodopa combined with Carbidopa or Benserazide).\n\nExclusion Criteria:\n\n1. Patient unable to stand an overnight (at least 12 hours) withdrawal of their immediate-release DRT (last extended-, delayed-, or controlled-release dosage must be taken minimum 24 hours prior to the test).\n2. Patient with known congestive heart failure, grades C and D, NYHA III and IV.\n3. Patient with dementia (i.e. major cognitive impairment) associated to MSA-P or PD,\n4. Patient with mild cognitive impairment, and unable to provide or understand informed consent, i.e. who does not have full capacity for discernment.\n5. Current participation to other clinical trials.\n6. Pregnant or lactating woman or willing to become pregnant.",{"count":68,"type":22},36,[70,71],"PHASE1","PHASE2","This study is aimed at patients with multi-system atrophy - parkinsonian type (P-MSA) or Parkinson's disease (PD) receiving dopaminergic drugs and suffering from orthostatic hypotension (OH).\n\nOH is a drop in blood pressure when standing, which can lead to symptoms of dizziness, lightheadedness, a black veil in front of the eyes and, when severe, can lead to fainting. HO is one of the symptoms present in AMS-P and PD.\n\nThe standard treatment for parkinsonian symptoms of slowness and stiffness is the administration of antiparkinsonian drugs containing dopamine. These dopaminergic drugs always contain 1) levodopa (which is the precursor of dopamine) and 2) an enzyme inhibitor, which may be either benserazide (in the case of Madopar® and its generics) or carbidopa (in the case of Sinemet® or Stalevo® and their generics) and whose role is to potentiate the effect of levodopa.\n\nIt has long been known that dopaminergic drugs aggravate HO. Through various mechanisms, this worsening of HO is linked as much to levodopa as to the enzyme inhibitor with which it is combined. However, investigators do not know the respective effects of these two molecules on HO.\n\nIn this study, investigators examine how the ratio of Carbidopa to levodopa affects HO in the various assays of the dopaminergic drug under study.",[74,29,75],"Multi-system Atrophy - Parkinsonian Type","Parkinson Disease",[65],"2026-01-28",{"date":79,"type":50},"2026-01-29",{"date":81,"type":50},"2025-07-18",{"date":54,"type":22},{"name":84,"class":57},"Julien Bally",2,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":23,"phases":97,"briefSummary":98,"conditions":99,"keywords":104,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":58},"100586803","epidural-electrical-stimulation-to-support-hemodynamic-management-in-individuals-with-parkinsons-disease-100586803","NCT06920134","Epidural Electrical Stimulation to Support Hemodynamic Management in Individuals With Parkinson's Disease","Study on Preliminary Safety and Efficacy of the ARC-IM Therapy to Support Hemodynamic Management in People With Typical and Atypical Parkinson's Disease","PD-HemON","Inclusion Criteria:\n\n1. \\> 18 years old\n2. Typical or Atypical PD (including but not limited to Multiple System Atrophy, Pure Autonomic Failure, Progressive Supranuclear Palsy)\n3. Confirmed orthostatic hypotension with a test for verticalization\n4. Confirmed symptomatic orthostatic hypotension that makes daily activities particularly challenging as determined by the study clinicians\n5. Must provide and sign the Informed Consent before any study-related procedures\n6. Stable medical, physical, and psychological conditions given participant indication as considered by Investigators;\n7. Able to understand and interact with the study team in French or English\n8. Agrees to comply in good faith with all conditions of the study and to attend all scheduled appointments\n\nExclusion Criteria:\n\n1. Diseases and conditions that would increase the morbidity and mortality of the implantation surgery\n2. The inability to withhold antiplatelet\u002Fanticoagulation agents perioperatively\n3. History of myocardial infarction or cerebrovascular events within the past 6 months\n4. Unstable or significant medical condition that is likely to interfere with study procedures or likely to confound study endpoint evaluations as determined by the Investigator\n5. History or presence of major psychiatric disorders or major neurocognitive disorders as considered by the Investigators in accordance with the treating physician and treating neurologist\n6. Major changes in PD treatment planned until the end of the main study phase (such as DBS or dopamine-pump implantation)\n7. Inability to follow study procedures.\n8. Spinal anatomical abnormalities precluding surgery\n9. Presence of any indications requiring frequent MRIs.\n10. Current pregnancy or current breastfeeding\n11. Lack of effective or acceptable contraception for women of childbearing capacity\n12. Intention to become pregnant during the study\n13. Unable or unwilling to effectively use the study system or related devices by the participant or caretaker, as determined by the investigator\n14. Participation in another interventional study that might confound study endpoint evaluations\n15. Enrolment of the investigator, his\u002Fher family members, employees, and other dependent persons","90 Years",{"count":96,"type":22},5,[25],"The PD-HemON study aims to evaluate the safety and preliminary efficacy of ARC-IM Therapy (Epidural Electrical Stimulation) to support hemodynamic management in people with typical and atypical Parkinson's Disease, who suffer from orthostatic hypotension.",[100,101,29,102,103],"Hypotension Symptomatic","Parkinson's Disease","Multiple System Atrophy (MSA) With Orthostatic Hypotension","Multiple System Atrophy - Parkinsonian Subtype (MSA-P)",[35,105,106,107],"parkinson's disease","autonomic failure","hypotension","2025-11-14",{"date":110,"type":50},"2025-11-18",{"date":112,"type":50},"2025-07-03",{"date":114,"type":22},"2031-05-01",{"name":116,"class":57},"Ecole Polytechnique Fédérale de Lausanne",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":23,"phases":126,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":58},"100608003","the-stand-up-study-100608003","NCT07195903","The STAND-UP Study","Evaluation of Supracardiac Venous Angioplasty and Stenting on Ortho- Static Intolerance and Orthostatic Hypotension - The STANDUP Study","Inclusion criteria :\n\n1. Age 18 years\n2. Diagnosed orthostatic intolerance or orthostatic hypotension not responding to standard medical management or complicated by supine hypertension\n3. Able to provide informed consent • Exclusion criteria:\n\n1\\. Pregnancy or breastfeeding 2. Active infection 3. Coagulopathy or contraindication to anticoagulation therapy",{"count":125,"type":22},100,[25],"Orthostatic hypotension (OH) and orthostatic intolerance (OI) are common conditions where blood pressure drops when standing up, causing dizziness, fainting, or fatigue. These affect up to 30% of adults over 65 and raise risks for heart disease, stroke, kidney problems, and more. Current medications often don't fully help and can cause side effects like high blood pressure when lying down.\n\nThe STANDUP study tests a new approach: using a minimally invasive procedure to open narrowed veins above the heart (supracardiac veins) that may block blood flow back to the heart. We believe fixing these blockages could improve blood pressure control and reduce symptoms. This is a 2-year study enrolling 100 adults (age 18+) with OH or OI that hasn't improved with standard treatments or is worsened by lying-down high blood pressure.\n\nWhat happens in the study? Participants get imaging (like X-rays and ultrasound) to check for vein narrowing. If needed, doctors use a thin tube (catheter) through a small skin puncture to inflate a tiny balloon (angioplasty) or place a small mesh tube (stent) to widen the veins. The procedure takes a few hours under local anesthesia, with monitoring for safety. Follow-up visits check symptoms, blood pressure, and quality of life at 2-4 weeks, 3 months, 6 months, 1 year, and 2 years.\n\nWho can join?\n\nAdults 18+ with diagnosed OH\u002FOI not helped by meds. Must give informed consent. Not eligible if: Pregnant, breastfeeding, actively infected, or unable to take blood thinners.\n\nPossible benefits: Better standing tolerance, fewer symptoms, improved daily life, less need for meds, and new knowledge on vein issues in OH\u002FOI.\n\nRisks: Rare but include bleeding, infection, stroke, vein clots, stent issues, radiation from imaging, or temporary symptom worsening. We'll monitor closely and report any problems.\n\nThis single-arm trial (no placebo group) will compare before-and-after results to see if the procedure helps. No study drug costs; covered by insurance or clinic. Led by Dr. Karthikeyan Arcot at St. Francis Hospital, Roslyn, NY. Contact for details.",[29,129],"Orthostatic Intolerance","2025-09-19",{"date":132,"type":50},"2025-09-29",{"date":134,"type":50},"2025-01-23",{"date":136,"type":22},"2030-01-01",{"name":138,"class":57},"St. Francis Hospital, New York"]